Welcome to our dedicated page for Medtronic plc news (Ticker: $MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medtronic plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medtronic plc's position in the market.
In a recent press release by Medtronic, Chief Scientific and Medical Officer Laura Mauri discusses the intersection of healthcare and technology in achieving longevity. While many Americans aspire to live past 90, the survey reveals a preference for a shorter, healthier life. Despite belief in healthcare technology, engagement in preventative measures remains low. Medtronic aims to bridge this gap by providing innovative solutions that enhance patient outcomes and experiences. By sharing four actions under the acronym T.E.C.H., individuals are encouraged to take charge of their health and well-being.
Medtronic's groundbreaking SMART clinical trial focusing on women with aortic stenosis marks a pivotal moment in women's health. The study compared Medtronic's Evolut transcatheter aortic heart valve system with Edwards Sapien, revealing superior performance of the Evolut system. Female-specific data from the trial sheds light on gender inequities in heart health care, emphasizing the need to address underrepresentation of women in clinical trials.
